Use of a dosimetry‐based radioiodine (RAI) protocol for treatment of benign hyperthyroidism optimises response while minimising exposure to ionising radiation
Authors' conclusion
This retrospective clinical study demonstrated that treatment with a dosimetry-based protocol for TMNG and GD achieved comparable success rates to fixed protocols while reducing RAI exposure for over a third of patients with GD and most patients with TMNG. This study also highlighted that RAI can successfully treat hyperthyroidism for some patients with activities lower than commonplace in clinical practise. No patient or disease specific modulators of treatment response were established in this study; however, the data supports a future prospective trial which further scrutinises the individual patient factors governing treatment response to RAI.
Study context
- Population
- Patients with benign hyperthyroidism (Graves' disease (GD) or Toxic Multinodular Goiter (TMNG)) treated with RAI
- Participants
- 204 patients
- Exposure
- Dosimetry-based RAI protocol vs fixed-activity RAI
- Dosimetryn = 53
- Fixedn = 151reference
- Outcome
- Success: non-hyperthyroid state
- Follow-up
- 1 year
Main finding
As reported in the abstract
Dosimetry success rate in GD
80.5%
Dosimetry success rate in TMNG
100%
Observational data: associations, not effects.
Further findings
| Outcome | Dosimetry | Fixed |
|---|---|---|
| Median activity administered | median 246 MBq | median 204 Mbq |
Received lower activity with dosimetry vs fixed
- GD
- 44%
- TMNG
- 70%
Successful treatment and reduced RAI exposure with dosimetry
- GD
- 36%
- TMNG
- 70%
- Overall
- 44%
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →